Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Consensus Rating of “Hold” from Analysts

Hyperion DeFi, Inc. (NASDAQ:HYPD) has been given an average recommendation of “Hold” by the five brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $4.5833.

A number of analysts recently issued reports on the company. Chardan Capital set a $7.75 price objective on Hyperion DeFi and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Cantor Fitzgerald assumed coverage on shares of Hyperion DeFi in a research report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price target for the company. Zacks Research upgraded shares of Hyperion DeFi to a “hold” rating in a report on Monday, December 29th. Wall Street Zen raised shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Thursday.

Hyperion DeFi Trading Up 4.1%

HYPD opened at $3.04 on Friday. The stock has a market capitalization of $24.85 million, a PE ratio of -0.75 and a beta of 2.69. Hyperion DeFi has a one year low of $0.85 and a one year high of $17.18. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The business’s 50 day moving average price is $3.68 and its 200 day moving average price is $6.80.

Hyperion DeFi (NASDAQ:HYPD) last posted its earnings results on Friday, November 14th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $0.36 million for the quarter. As a group, equities research analysts expect that Hyperion DeFi will post -41.6 EPS for the current year.

Insider Transactions at Hyperion DeFi

In other news, Director Michael S. Geltzeiler bought 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were purchased at an average price of $3.01 per share, with a total value of $90,300.00. Following the purchase, the director owned 88,015 shares in the company, valued at approximately $264,925.15. The trade was a 51.71% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ellen R. Strahlman bought 11,856 shares of the stock in a transaction that occurred on Monday, December 29th. The shares were purchased at an average price of $3.61 per share, with a total value of $42,800.16. Following the completion of the acquisition, the director directly owned 34,869 shares in the company, valued at $125,877.09. This trade represents a 51.52% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 189,204 shares of company stock worth $611,467 over the last quarter. 10.86% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hyperion DeFi stock. Formidable Asset Management LLC bought a new position in shares of Hyperion DeFi, Inc. (NASDAQ:HYPD) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 23,380 shares of the company’s stock, valued at approximately $83,000. Formidable Asset Management LLC owned 0.29% of Hyperion DeFi as of its most recent SEC filing. 25.84% of the stock is currently owned by institutional investors and hedge funds.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.